JP2019506435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506435A5 JP2019506435A5 JP2018544832A JP2018544832A JP2019506435A5 JP 2019506435 A5 JP2019506435 A5 JP 2019506435A5 JP 2018544832 A JP2018544832 A JP 2018544832A JP 2018544832 A JP2018544832 A JP 2018544832A JP 2019506435 A5 JP2019506435 A5 JP 2019506435A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- hpv
- pharmaceutical composition
- dose
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 241000701806 Human papillomavirus Species 0.000 claims 13
- 229960002566 papillomavirus vaccine Drugs 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 230000003902 lesion Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 201000000849 skin cancer Diseases 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 5
- 229940121354 immunomodulator Drugs 0.000 claims 5
- 230000002584 immunomodulator Effects 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 239000003589 local anesthetic agent Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108010050904 Interferons Chemical class 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- -1 cyclomethicaine Chemical compound 0.000 claims 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims 2
- 229950010160 dimethocaine Drugs 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- 229960004919 procaine Drugs 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 229940124551 recombinant vaccine Drugs 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010059313 Anogenital warts Diseases 0.000 claims 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 1
- 101000889812 Enterobacteria phage T4 Endonuclease Proteins 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical class OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003831 articaine Drugs 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- 229960003150 bupivacaine Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001747 cinchocaine Drugs 0.000 claims 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003976 etidocaine Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims 1
- 229960002993 ingenol mebutate Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- 229960003981 proparacaine Drugs 0.000 claims 1
- 229950003255 propoxycaine Drugs 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Chemical class COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960001549 ropivacaine Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 229960002372 tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 150000002266 vitamin A derivatives Chemical class 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021108667A JP7732784B2 (ja) | 2016-02-27 | 2021-06-30 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
| JP2023092142A JP2023110038A (ja) | 2016-02-27 | 2023-06-05 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300785P | 2016-02-27 | 2016-02-27 | |
| US62/300,785 | 2016-02-27 | ||
| US201662328487P | 2016-04-27 | 2016-04-27 | |
| US62/328,487 | 2016-04-27 | ||
| US201662338183P | 2016-05-18 | 2016-05-18 | |
| US62/338,183 | 2016-05-18 | ||
| US201762444576P | 2017-01-10 | 2017-01-10 | |
| US62/444,576 | 2017-01-10 | ||
| US201762455434P | 2017-02-06 | 2017-02-06 | |
| US62/455,434 | 2017-02-06 | ||
| PCT/US2017/019433 WO2017147475A1 (en) | 2016-02-27 | 2017-02-24 | Method and composition for treating cancer or skin lesion using a vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021108667A Division JP7732784B2 (ja) | 2016-02-27 | 2021-06-30 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506435A JP2019506435A (ja) | 2019-03-07 |
| JP2019506435A5 true JP2019506435A5 (enExample) | 2020-04-02 |
Family
ID=59686556
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544832A Pending JP2019506435A (ja) | 2016-02-27 | 2017-02-24 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
| JP2021108667A Active JP7732784B2 (ja) | 2016-02-27 | 2021-06-30 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
| JP2023092142A Pending JP2023110038A (ja) | 2016-02-27 | 2023-06-05 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021108667A Active JP7732784B2 (ja) | 2016-02-27 | 2021-06-30 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
| JP2023092142A Pending JP2023110038A (ja) | 2016-02-27 | 2023-06-05 | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3419661A4 (enExample) |
| JP (3) | JP2019506435A (enExample) |
| KR (1) | KR102873848B1 (enExample) |
| CN (1) | CN108883168A (enExample) |
| AU (1) | AU2017223970B2 (enExample) |
| BR (1) | BR112018067550A2 (enExample) |
| CA (1) | CA3015519A1 (enExample) |
| CL (1) | CL2018002438A1 (enExample) |
| CO (1) | CO2018009205A2 (enExample) |
| HK (1) | HK1256935A1 (enExample) |
| IL (1) | IL261340B2 (enExample) |
| MX (1) | MX2018010338A (enExample) |
| MY (1) | MY194694A (enExample) |
| SG (1) | SG11201807080UA (enExample) |
| WO (1) | WO2017147475A1 (enExample) |
| ZA (1) | ZA201805679B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021013069A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒11型l1蛋白 |
| IL302098A (en) * | 2020-10-12 | 2023-06-01 | Hpvvax Llc | The composition and method for treating cancer using a vaccine as a first active therapeutic ingredient in combination with a second active ingredient |
| KR20250089555A (ko) * | 2022-10-31 | 2025-06-18 | 파이로자스 인크 | 면역요법 조성물 및 사용 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| CN107252489A (zh) * | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| PE20120563A1 (es) * | 2009-06-25 | 2012-05-17 | Glaxosmithkline Biolog Sa | Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| CN104203270A (zh) * | 2012-03-18 | 2014-12-10 | 葛兰素史密丝克莱恩生物有限公司 | 针对人乳头状瘤病毒的接种方法 |
| US20130251782A1 (en) * | 2012-03-22 | 2013-09-26 | Leo Laboratories Limited | Topical application of ingenol mebutate with occlusion |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3054994A4 (en) * | 2013-10-13 | 2017-10-11 | The Board of Trustees of the University of Arkansas | Human papilloma virus therapeutic vaccine |
| AU2015204503B2 (en) * | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
| AU2015335652B2 (en) * | 2014-10-24 | 2020-07-02 | Hpvvax, Llc. | Cancer and skin lesion treatment |
-
2017
- 2017-02-24 AU AU2017223970A patent/AU2017223970B2/en active Active
- 2017-02-24 CN CN201780016785.3A patent/CN108883168A/zh active Pending
- 2017-02-24 MX MX2018010338A patent/MX2018010338A/es unknown
- 2017-02-24 BR BR112018067550-4A patent/BR112018067550A2/pt unknown
- 2017-02-24 KR KR1020187027123A patent/KR102873848B1/ko active Active
- 2017-02-24 JP JP2018544832A patent/JP2019506435A/ja active Pending
- 2017-02-24 WO PCT/US2017/019433 patent/WO2017147475A1/en not_active Ceased
- 2017-02-24 CO CONC2018/0009205A patent/CO2018009205A2/es unknown
- 2017-02-24 SG SG11201807080UA patent/SG11201807080UA/en unknown
- 2017-02-24 CA CA3015519A patent/CA3015519A1/en active Pending
- 2017-02-24 HK HK18116062.9A patent/HK1256935A1/zh unknown
- 2017-02-24 EP EP17757336.7A patent/EP3419661A4/en active Pending
- 2017-02-24 MY MYPI2018001489A patent/MY194694A/en unknown
-
2018
- 2018-08-23 IL IL261340A patent/IL261340B2/en unknown
- 2018-08-24 CL CL2018002438A patent/CL2018002438A1/es unknown
- 2018-08-24 ZA ZA201805679A patent/ZA201805679B/en unknown
-
2021
- 2021-06-30 JP JP2021108667A patent/JP7732784B2/ja active Active
-
2023
- 2023-06-05 JP JP2023092142A patent/JP2023110038A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500718A5 (enExample) | ||
| JP2012087150A5 (enExample) | ||
| Nimbalkar et al. | Tuberculin purified protein derivative immunotherapy in the treatment of viral warts | |
| JP2020528911A5 (enExample) | ||
| Shin et al. | New onset guttate psoriasis following pandemic H1N1 influenza vaccination | |
| JP2019506435A5 (enExample) | ||
| JP2023110038A (ja) | ワクチンを使用して癌または皮膚病変を治療するための方法および組成物 | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| CO6341567A2 (es) | Vacuna contra el virus de papiloma humano | |
| JP2015044878A5 (enExample) | ||
| JP2023012539A (ja) | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 | |
| JP6663438B2 (ja) | 癌および皮膚病変の治療 | |
| JP2020509035A5 (enExample) | ||
| Liang et al. | Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review | |
| JP2017531699A5 (enExample) | ||
| JP2023546073A (ja) | 第１の治療有効成分としてのワクチンを、第２の有効成分と組み合わせて使用する、癌を治療するための組成物及び方法 | |
| CN116270990A (zh) | Adam17在制备治疗效应性cd8+t细胞分化相关疾病药物中的用途 | |
| Mohta et al. | A curious case of development of verruca vulgaris over the site of autoimplantation: Subsequently treated with measles, mumps and rubella vaccine | |
| US20230414741A1 (en) | Method and compositon for treating cancer using a vaccine | |
| RU2017102042A (ru) | Новое соединение, выделенное из pseudolysimachion rotundum var. subintegrum, с высоким содержанием активного ингредиента, композиция, содержащая указанное соединение, для предотвращения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких, и их применение | |
| CN118526581A (zh) | 双氢青蒿素dha在制备抗肝癌药物中的应用 | |
| CN109771400A (zh) | 构树宁e的医药新用途 |